The Shkreli Pill

In this episode, Martin examines how a single FDA-related hint caused QURE stock to surge and what it reveals about market sensitivity to biotech news. He also discusses his outlook on SPRB, speculating on when it could reach the $500 mark, and provides analysis of Uniqure and UnitedHealth stocks within the broader healthcare landscape.

In this episode, Martin shares that Sarepta has grown to represent 40% of his portfolio and explains the reasoning behind his conviction. He discusses the recent crash in QURE stock, provides an updated forecast for Biohaven, and analyzes what he views as an emerging bubble in Palantir.

In this episode, Martin analyzes Walmart’s valuation and explains why he believes it signals a broader market shift toward caution and liquidity. He also reviews Reddit’s recent earnings, interpreting them as a warning sign for speculative stocks and overvalued growth plays.

In this episode, Martin examines Berkshire Hathaway’s record $382 billion cash position and what it signals about market sentiment and opportunity. Through a compilation of key investing insights from recent streams, he shares the lessons and “gems” he believes are most relevant for navigating today’s uncertain environment.

In this episode, Martin reveals which meme stock he’s currently long on and explains the reasoning behind the position. He also provides an analysis of Taiwan Semiconductor, discusses recent developments with Tesla and Apple, and ties these insights into his broader market strategy.

In this episode, Martin reflects on growing market uncertainty and the idea that “nothing is safe anymore.” He highlights why he sees Biohaven as having 3x potential, conducts a detailed analysis of Berkshire Hathaway’s stock, and shares updated perspectives on Apple and Meta within the broader market context.

In this episode, Martin evaluates whether Meta has become a clear buying opportunity at its current valuation. He compares Meta’s positioning to Google, Apple, and Nvidia, offering his stock forecasts for each and outlining the key factors driving his outlook on big tech performance.

In this episode, Martin draws parallels between Intel’s historical rise and Nvidia’s current trajectory, highlighting the patterns that concern him as an investor. He provides an in-depth stock analysis of Nvidia, discusses potential risks ahead, and offers updated thoughts on SPRB and its place in his broader market view.

In this episode, Martin discusses his latest options trade on CAPR and how he’s positioning ahead of potential market moves. He reviews new data related to Summit stock and examines Nvidia’s growing involvement in quantum computing, outlining how these developments could shape his upcoming strategies.

In this episode, Martin reacts to new BTQ contract developments that have raised concerns about his position. He discusses the implications of the news for Quantum, explores the role of elliptic curve cryptography in modern finance, and connects these concepts to the broader outlook for Bitcoin.

In this episode, Martin reviews Intellia’s recent performance and explains why the outlook doesn’t appear promising. He discusses his upcoming short thesis on CAPR and provides a detailed analysis of Summit stock, focusing on valuation, catalysts, and potential risks.

In this episode, Martin points to a Korean stock he believes deserves close attention and explains why he’s bullish on RVMD and Nvidia’s AI GPU positioning. He also references insights from Nassim Taleb to frame his broader perspective on market risk and asymmetric opportunity.

In this episode, Martin explores how the definition of an asset has shifted in today’s market environment and what that means for investors navigating inflated valuations. He highlights one key Warren Buffett principle that he believes is essential for surviving speculative bubbles and explains why he personally avoids trading options despite their popularity.

In this episode, Martin analyzes the “Tiger Cub” style of investing, explaining why their trading approach has appeared nearly invincible in certain market cycles. He also challenges the common perception of Palantir, arguing that it functions more like a hedge fund than a traditional tech company.

In this episode, Martin argues that there’s a largely overlooked segment of the market presenting strong value opportunities and urges investors to act quickly. He also discusses his views on shorting Tesla, reflects on Warren Buffett’s investment philosophy in the current environment, and provides an update on Beyond Meat (BYND) stock.

In this episode, Martin makes a spontaneous $5,000 bet with a retail trader during a live stream and later announces his decision to step away from streaming. Before signing off, he shares key insights on covering short positions, highlighting the tactics and timing that separate disciplined execution from emotional trading.

In this episode, Martin reacts to Google’s unexpected announcement related to Quantum and examines its implications for the tech and AI sectors. He questions whether Charlie Munger’s long-held views on technology investing still hold up and evaluates Jim Cramer’s approach as a trader. Martin also provides an update on SPRB and how it fits into his current market outlook.

In this episode, Martin reveals that his portfolio is up 386% and breaks down the trades and strategies that led to this result. He discusses his positions in Beyond Meat (BYND), Natera, Bitcoin, and Quantum, explaining how each contributed to his performance and what he’s watching next in the market.

In this episode, Martin claims that the next GameStop-style setup has arrived and walks through what he calls his “perfect short” strategy. He analyzes the renewed surge in Beyond Meat (BYND) stock, exploring the mechanics behind the pump and outlining why he sees it as a prime opportunity for short sellers.

In this episode, Martin breaks down what he believes is the real reason behind the recent surge in Beyond Meat’s stock price. He also engages in a lively debate with members of the BYND community, examining differing perspectives on the company’s fundamentals, hype, and long-term viability.

In this episode, Martin comments on a surprising market trend involving Korean investors turning to Beyond Meat and argues that it could signal a market top. He also explores a potential new long position in RVMD (Revolution Medicines), analyzing its fundamentals and growth prospects.

In this compilation episode, Martin walks through historic and current market bubbles, focusing on the patterns he believes consistently appear right before they collapse. Using examples from past streams, he illustrates these warning signs and how he identifies them in real time while trading.

In this episode, Martin discusses his shift toward real estate investing and reflects on what that transition means for his trading journey. He also analyzes IDEAYA Biosciences, explaining why he views the stock as a promising long position and how it fits into his broader portfolio strategy.

In this episode, Martin discusses whether it still makes sense to hold Nvidia amid shifting market dynamics. He explores how energy markets are adapting to the growing demands of AI infrastructure and provides analysis of OKLO stock. The episode also touches on recent biotech stories that Martin views as potential scams.

In this episode, Martin humorously recounts the personal and financial stress of maintaining his margin account during the ongoing Quantum run. Blending candid storytelling with market commentary, he offers insight into the emotional side of trading under pressure.